Protocol Ledger

NCT07496450 · Phase III · ACTIVE NOT RECRUITING

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

Interventional Phase III clinical trial protocol NCT07496450 sponsored by ModernaTX in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-23 Enrollment: 4,050 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07496450
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)4,050 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07496450
Protocol FieldVerified Registry Value
NCT IdentifierNCT07496450
Consolidated Lead SponsorModernaTX
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment4,050 participants (ACTUAL)
Registered Start Date2026-03-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07496450
Hospital Research SiteLocationSite Profile
Velocity Clinical Research (Meridian)Meridian, IDOpen Hospital Dossier ->
Velocity Clinical Research (East Greenwich)East Greenwich, RIOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Moderna across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI